We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel PCR Testing Device Represents Technological Leap in POC Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 15 May 2023

Testing for infectious diseases is vital for global health. More...

Present testing methods, including immunochemistry and nucleic acid detection, play a crucial role in combating infectious diseases, but they also have significant drawbacks. Consequently, healthcare providers and patients often have to choose between fast and affordable results with limited sensitivity, or slower, more accurate results which often arrive too late to significantly impact outcomes. This situation often leads to lost opportunities for more effective treatment of infectious diseases. Now, a novel testing device offers a significant advancement in point-of-care infectious disease testing, potentially expanding the scope of telemedicine interactions between healthcare professionals and their patients.

Nuclein’s (Austin, TX, USA) Anywhere PCR Test is a PCR testing device designed to run a real-time PCR reaction inside an all-in-one self-test, infectious disease testing solution and delivers battery-powered, sample-to-answer results in less than an hour. This allows immediate, self-testing results to be available anywhere at the push of a button, utilizing the same standard real-time PCR technology employed by the U.S. Centers for Disease Control and Prevention (CDC), other government bodies, and commercial laboratories.

The testing device is designed to accept a saliva sample directly from the patient. The diagnostic process can be initiated by simply pressing a button, after which the device automatically prepares the sample for analysis. Test results are then automatically displayed on the LCD screen within an hour, indicating either a negative or positive result. The capacity to provide immediate results in less than an hour potentially makes the Nuclein Anywhere PCR Test an exceptionally useful tool for detecting infectious diseases, facilitating faster and more informed decision-making, ultimately leading to improved outcomes.

Related Links:
Nuclein 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Molecular Diagnostics

view channel
Image:Graphical Abstract (Victori P, Hua K, Twigger AJ, et al. Tumor digital twins uncover therapeutic strategies in triple-negative breast cancer. Cell Reports Medicine, 2026. doi:10.1016/j.xcrm.2026.103119.)

Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. Its tumor cells lack estrogen receptors, progesterone receptors, and... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.